A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) (NCT06349473)
A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).
Who can join: Review the eligibility criteria below.
Location: California Clinical Trials Medical Group (CCTMG) — Glendale, California
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- California Clinical Trials Medical Group (CCTMG) — Glendale, California
- Children's Hospital Los Angeles — Los Angeles, California
- Rush University Medical Center — Chicago, Illinois
- LA Center for Bleeding and Clotting Disorders - Metairie — Metairie, Louisiana
- University of Michigan Hospitals - Michigan Medicine — Ann Arbor, Michigan
- Washington University School of Medicine — St Louis, Missouri
- Brody School of Medicine at East Carolina University — Greenville, North Carolina
- Penn State Milton S Hershey Medical Center Pediatrics — Hershey, Pennsylvania
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program — Philadelphia, Pennsylvania
- McMaster University Medical Centre, Hamilton Health Sciences — Hamilton, Ontario
📞 Contact the Study Coordinator
Phone: (925) 490-0278
Email: inf@equilibrabioscience.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Healthy Participants
- A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults — Brooklyn, Maryland
- The Effect of Heat Pads and Foam Rolling on Strength in Athletes. — Redlands, California
- A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants — Madison, Wisconsin
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. — Anaheim, California
- A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) — Glendale, California
- A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants — Glendale, California
Explore by condition: All Healthy Participants clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.